-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Akebia Therapeutics (NASDAQ:AKBA) Coverage Initiated by Analysts at StockNews.com
Akebia Therapeutics (NASDAQ:AKBA) Coverage Initiated by Analysts at StockNews.com
StockNews.com assumed coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a report published on Saturday. The firm issued a hold rating on the biopharmaceutical company's stock.
Separately, HC Wainwright decreased their price target on Akebia Therapeutics from $2.00 to $1.25 in a research report on Monday, May 16th. Seven investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $1.75.
Get Akebia Therapeutics alerts:Akebia Therapeutics Stock Down 2.3 %
NASDAQ AKBA opened at $0.37 on Friday. The firm has a market cap of $67.47 million, a PE ratio of -0.39 and a beta of 1.50. Akebia Therapeutics has a one year low of $0.30 and a one year high of $3.35. The stock's 50 day simple moving average is $0.40 and its 200 day simple moving average is $0.86. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.30 and a quick ratio of 1.15.
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.54. The business had revenue of $126.76 million for the quarter, compared to analyst estimates of $49.10 million. Akebia Therapeutics had a negative return on equity of 197.12% and a negative net margin of 55.04%. During the same period in the prior year, the company earned ($0.51) EPS. As a group, sell-side analysts forecast that Akebia Therapeutics will post -0.44 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of AKBA. Millennium Management LLC lifted its holdings in Akebia Therapeutics by 65.8% during the 2nd quarter. Millennium Management LLC now owns 5,354,175 shares of the biopharmaceutical company's stock worth $1,891,000 after buying an additional 2,124,161 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Akebia Therapeutics by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 14,402,988 shares of the biopharmaceutical company's stock worth $10,339,000 after buying an additional 1,167,319 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Akebia Therapeutics by 367.4% during the 2nd quarter. AQR Capital Management LLC now owns 862,168 shares of the biopharmaceutical company's stock worth $304,000 after buying an additional 677,703 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Akebia Therapeutics by 23.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,593,841 shares of the biopharmaceutical company's stock worth $5,862,000 after buying an additional 498,078 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Akebia Therapeutics by 47.7% during the 2nd quarter. Renaissance Technologies LLC now owns 1,482,300 shares of the biopharmaceutical company's stock worth $523,000 after buying an additional 478,973 shares in the last quarter. Institutional investors and hedge funds own 55.34% of the company's stock.
About Akebia Therapeutics
(Get Rating)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
Featured Stories
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- 3 WallStreetBets Stocks Wall Street is (Mostly) Bullish On
- Does Micron's Dividend Increase Mean It's Time To Buy?
- What is the NASDAQ Stock Exchange?
- Should You Be Bullish On Barrick Gold?
- The Institutions Choose Dollar General For The 2nd Half
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com assumed coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a report published on Saturday. The firm issued a hold rating on the biopharmaceutical company's stock.
斯托克新聞網在週六發佈的一份報告中對木通治療公司(納斯達克：AKBA-GET評級)的股票進行了報道。該公司對這家生物製藥公司的股票發佈了持有評級。
Separately, HC Wainwright decreased their price target on Akebia Therapeutics from $2.00 to $1.25 in a research report on Monday, May 16th. Seven investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $1.75.
另外，在5月16日星期一的一份研究報告中，HC Wainwright將他們對木通治療的目標價從2.00美元下調至1.25美元。根據MarketBeat.com的數據，七位投資分析師對該股的評級為持有，該公司目前的平均評級為持有，共識目標價為1.75美元。
Akebia Therapeutics Stock Down 2.3 %
木通治療類股下跌2.3%
NASDAQ AKBA opened at $0.37 on Friday. The firm has a market cap of $67.47 million, a PE ratio of -0.39 and a beta of 1.50. Akebia Therapeutics has a one year low of $0.30 and a one year high of $3.35. The stock's 50 day simple moving average is $0.40 and its 200 day simple moving average is $0.86. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.30 and a quick ratio of 1.15.
納斯達克AKBA上週五開盤報0.37美元。該公司市值為6747萬美元，市盈率為-0.39，貝塔係數為1.50。木通治療公司的一年低點為0.30美元，一年高位為3.35美元。該股的50日簡單移動均線切入位為0.40美元，200日簡單移動均線切入位為0.86美元。該公司的債務權益比為0.51，流動比率為1.30，速動比率為1.15。
Institutional Inflows and Outflows
機構資金流入和流出
Several large investors have recently bought and sold shares of AKBA. Millennium Management LLC lifted its holdings in Akebia Therapeutics by 65.8% during the 2nd quarter. Millennium Management LLC now owns 5,354,175 shares of the biopharmaceutical company's stock worth $1,891,000 after buying an additional 2,124,161 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Akebia Therapeutics by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 14,402,988 shares of the biopharmaceutical company's stock worth $10,339,000 after buying an additional 1,167,319 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Akebia Therapeutics by 367.4% during the 2nd quarter. AQR Capital Management LLC now owns 862,168 shares of the biopharmaceutical company's stock worth $304,000 after buying an additional 677,703 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Akebia Therapeutics by 23.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,593,841 shares of the biopharmaceutical company's stock worth $5,862,000 after buying an additional 498,078 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Akebia Therapeutics by 47.7% during the 2nd quarter. Renaissance Technologies LLC now owns 1,482,300 shares of the biopharmaceutical company's stock worth $523,000 after buying an additional 478,973 shares in the last quarter. Institutional investors and hedge funds own 55.34% of the company's stock.
幾家大型投資者最近買賣了AKBA的股票。千禧管理公司在第二季度增持了木通治療公司65.8%的股份。Millennium Management LLC現在擁有這家生物製藥公司5,354,175股票，價值1,891,000美元，上個季度又購買了2,124,161股票。先鋒集團(Vanguard Group Inc.)第一季度增持木通治療公司的股份8.8%。先鋒集團現在持有這家生物製藥公司14,402,988股股票，價值10,339,000美元，上個季度又購買了1,167,319股。AQR資本管理有限責任公司在第二季度增持了木通治療公司的股份367.4%。AQR Capital Management LLC現在持有這家生物製藥公司862,168股股票，價值304,000美元，上個季度又購買了677,703股。Dimension Fund Advisors LP在第四季度將其在木通治療公司的持股增加了23.8%。Dimension Fund Advisors LP現在擁有這家生物製藥公司2,593,841股股票，價值5,862,000美元，上個季度又購買了498,078股。最後，復興技術有限責任公司在第二季度增持了47.7%的木通治療公司的股份。復興科技有限責任公司現在擁有這家生物製藥公司1,482,300股票，價值523,000美元，在上個季度又購買了478,973股票。機構投資者和對衝基金持有該公司55.34%的股票。
About Akebia Therapeutics
木通治療公司簡介
(Get Rating)
(獲取評級)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
木通治療公司是一家生物製藥公司，專注於腎臟疾病患者治療藥物的開發和商業化。該公司的主要研究產品候選產品是vadustat，這是一種口服療法，正處於第三階段開發，用於治療依賴透析和非透析依賴的成年患者的慢性腎臟疾病(CKD)引起的貧血。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- 3 WallStreetBets Stocks Wall Street is (Mostly) Bullish On
- Does Micron's Dividend Increase Mean It's Time To Buy?
- What is the NASDAQ Stock Exchange?
- Should You Be Bullish On Barrick Gold?
- The Institutions Choose Dollar General For The 2nd Half
- 免費獲取StockNews.com關於木通治療的研究報告(AKBA)
- WallStreetBets股票華爾街(大多)看好
- 美光增加股息是否意味着是時候買入了？
- 什麼是納斯達克證券交易所？
- 你應該看好巴里克·戈爾德嗎？
- 機構選擇美元通貨作為下半年
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受木通治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對木通治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧